Infosys launches SAP-based personalized medicine solution for pharmaceutical cos

The solution incorporates into an existing business process with minimal disruptions, reducing implementation time, thus enabling quicker product launches for pharma companies, it said. "With rapid growth in digital technologies and advances in biology, the personalised medicine market is projected to grow significantly, and we see a huge opportunity in this space.

Infosys launches SAP-based personalized medicine solution for pharmaceutical cos
Representative Image Image Credit: PR Newswire
  • Country:
  • India

IT services major Infosys on Monday launched a personalized medicine solution for the pharmaceutical industry. The solution leverages SAP S/4HANA, the SAP C/4HANA suite, the SAP Analytics Cloud solution, and SCI platform to derive intelligent insights, enabling pharmaceutical companies to address critical business and regulatory requirements while delivering personalized experiences to patients, Infosys said in a statement.

The modular solution uses advanced analytics to manage individual patient treatment lifecycle from enrollment and scheduling to post medical treatments and can notably reduce patient treatment lifecycle, it added. The solution uses Internet of Things (IoT) and blockchain to manage critical cold chains and outcome-based invoicing. The solution incorporates into an existing business process with minimal disruptions, reducing implementation time, thus enabling quicker product launches for pharma companies, it said.

"With rapid growth in digital technologies and advances in biology, the personalized medicine market is projected to grow significantly, and we see a huge opportunity in this space. Digital technologies can help pharma companies accelerate their time to market and provide better patient experiences," Infosys SVP and Global Head of Life Sciences Subhro Mallik said.

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.